Enter inventor name

EPO Patents = 1

Average Co-Inventor Count = 6.9

ph-index = 6

Forward Citations = 164(Granted Patents)

Location History:

NY, NY (US) (2009)
New York, NY (US) (1998 - 2013)

Company Filing History:

19 out of 526

Ludwig Institute for Cancer Research Limited

patents

9 out of 572

Memorial Sloan Kettering Cancer Center

The New York Hospital-Cornell Medical Center

patents

5. 6 out of 832,966

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2013

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8541202 - Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein (2013-09-24),

2. 8142786 - Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein (2012-03-27),

3. 8071717 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2011-12-06),

4. 7888100 - Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein (2011-02-15),

5. 7795409 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof (2010-09-14),

6. 7622568 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2009-11-24),

7. 7354992 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2008-04-08),

8. 7335467 - Breast cancer antigens (2008-02-26),

9. 7314721 - Small cell lung cancer associated antigens and uses therefor (2008-01-01),

10. 7132507 - Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses (2006-11-07),

11. 7115729 - Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53 (2006-10-03),

12. 6911529 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2005-06-28),

13. 6830924 - Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof (2004-12-14),

14. 6774226 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof (2004-08-10),

15. 6723832 - Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof (2004-04-20),

Title: Innovations by Ali O Gure in Cancer Research

Introduction

Ali O Gure is a prominent inventor based in New York, NY, who has made significant contributions to cancer research through his innovative inventions. With a remarkable total of 26 patents, Gure has focused on developing methods and peptides that enhance therapeutic and diagnostic outcomes in immunology.

Latest Patents

Among his latest inventions is the "Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein." This invention revolves around peptides that effectively bind to MHC Class I and MHC Class II molecules, proving to be beneficial in various therapeutic and diagnostic contexts. The importance of these peptides lies in their potential to improve cancer treatments and patient outcomes.

Career Highlights

Gure has collaborated with notable organizations such as the Ludwig Institute for Cancer Research and the Cornell Research Foundation. His work within these esteemed institutions has furthered advancements in the understanding of immune responses to cancer and the development of targeted therapies.

Collaborations

Throughout his career, Ali O Gure has worked alongside esteemed colleagues, including Yao-tseng Chen and Matthew J Scanlan. These collaborations have facilitated a sharing of ideas and research, contributing to the overall impact of their work in the field of cancer immunology.

Conclusion

With a solid portfolio of patents and impactful collaborations, Ali O Gure continues to be a pivotal figure in the realm of cancer research. His innovative approaches, particularly involving immunogenic peptides, underscore his commitment to advancing therapeutic solutions and improving patient care in oncology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com